tirzepatide for type 2 diabetes FDA approves new version of drug Mounjaro to be sold weight loss NICE recommends Lilly's tirzepatide for
Description
Its observational and not proof of causation, but the signal is compelling
Retatrutide is studied in research settings because of its relationship with GLP-1, GIP and glucagon receptor pathways
The mean weight loss among patients prescribed GLP-1 analogue monotherapy at 12 months was 11.42kg, SD 9.95 (9.6% TBWL)
Here is what the data show, from GI effects to the thyroid boxed warning.
Rather, it encompasses the overall goal of improving ones well-being. In this regard, []
